OSE Immunotherapeutics Receives First Grant of Patent for Use of Tedopi® After Failure of PD-1 or PD-L1 Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients – 25 /01/2022 at 6:30 PM

A grant agreement issued by the Japanese Patent Office

This new patent will protect Tedopi® until 2037

Nantes, France – January 25, 2022, 6:30 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that the Japanese Patent Office has issued an agreement to grant a new patent protecting the use of Tedopi® , a combination of neo-epitopes, after failure of immune checkpoint inhibitor therapy in HLA-A2 positive patients with cancer. This patent will strengthen the international intellectual property of Tedopi® and will provide new protection for the product until 2037.